MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
PerkinElmer DSO Ratio 2011-2026 | PKI
Annual DSO Ratio PerkinElmer
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 92.2 | 87.6 | 92.9 | 91.3 | 250 | - | 91.8 | 83.1 | 73.4 | 72 | - | 76.8 | 79.2 | 77.9 | 76.4 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 250 | 72 | 95.7 |
Quarterly DSO Ratio PerkinElmer
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 87.6 | 81 | 85.8 | - | 80 | 78.3 | 85.8 | - | 86.5 | 78.1 | 81.1 | - | 94.4 | 95.5 | 100 | 71.6 | 103 | 73.2 | 34.1 | - | 71.3 | 75 | 95.9 | 83.3 | 93.6 | 91.6 | 95.5 | 76.3 | 85.6 | 82.1 | 84 | 78.5 | 90.9 | 92.1 | 85.8 | 68.7 | 78 | 74.2 | 40 | - | 68 | 68 | 76.7 | 70.6 | 79.2 | 77.2 | 80.6 | 72 | 81.6 | 79 | 83.7 | 72.8 | 81.8 | 79.9 | 72.7 | 69.5 | 74.8 | 69.3 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 103 | 34.1 | 79.6 |
DSO Ratio of other stocks in the Diagnostics research industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
145 | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
63.8 | $ 111.3 | -3.12 % | $ 33.8 B |  USA |
|
Akumin
AKU
|
57.4 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Biocept
BIOC
|
112 | - | -13.05 % | $ 7.29 M | USA |
 |
Aspira Women's Health
AWH
|
1.17 K | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
291 | - | -61.36 % | $ 2.46 M | USA |
 |
CareDx, Inc
CDNA
|
51.5 | $ 20.8 | -5.07 % | $ 1.11 B | USA |
 |
Chembio Diagnostics
CEMI
|
66.3 | - | 0.22 % | $ 16.8 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
90.8 | - | - | $ 562 M |  Britain |
 |
Co-Diagnostics
CODX
|
94.7 | $ 1.53 | -6.13 % | $ 2.04 M | USA |
 |
Castle Biosciences
CSTL
|
49.2 | $ 24.24 | -1.86 % | $ 673 M | USA |
 |
DermTech
DMTK
|
80.6 | - | -11.32 % | $ 2.94 M | USA |
 |
Global Cord Blood Corporation
CO
|
112 | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
67.2 | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
11.7 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
122 | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
65 | $ 163.84 | -1.77 % | $ 8.12 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
98.1 | - | - | $ 10.7 B | USA |
 |
Enzo Biochem
ENZ
|
50.3 | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
30.8 | - | - | $ 19.8 B | USA |
 |
Guardant Health
GH
|
46.1 | $ 83.41 | 0.35 % | $ 10.5 B | USA |
 |
Fulgent Genetics
FLGT
|
77.4 | $ 14.8 | -3.27 % | $ 447 M | USA |
 |
Heska Corporation
HSKA
|
40.8 | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
101 | - | -20.0 % | $ 1.06 M | USA |
 |
Interpace Biosciences
IDXG
|
66.9 | $ 1.99 | 2.9 % | $ 8.8 M | USA |
 |
Illumina
ILMN
|
61.3 | $ 120.37 | -5.16 % | $ 19.1 B | USA |
 |
QIAGEN N.V.
QGEN
|
30.8 | - | - | $ 10.6 B |  Niderland |
 |
Biomerica
BMRA
|
57.7 | $ 2.16 | -1.22 % | $ 4.96 M | USA |
 |
Lantheus Holdings
LNTH
|
80.5 | $ 81.17 | -2.85 % | $ 5.48 B | USA |
 |
ICON Public Limited Company
ICLR
|
68.5 | $ 116.17 | 13.35 % | $ 9.58 B |  Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
52.9 | $ 257.14 | -0.94 % | $ 21.4 B | USA |
 |
Medpace Holdings
MEDP
|
50.4 | $ 413.59 | 0.93 % | $ 11.9 B | USA |
 |
Motus GI Holdings
MOTS
|
77.2 | - | -34.28 % | $ 263 K |  Israel |
 |
NeoGenomics
NEO
|
77.7 | $ 8.96 | -0.67 % | $ 1.15 B | USA |
 |
Neogen Corporation
NEOG
|
66.6 | $ 9.01 | -3.53 % | $ 1.95 B | USA |
 |
National Research Corporation
NRC
|
29.4 | $ 16.54 | -1.78 % | $ 370 M | USA |
 |
Invitae Corporation
NVTA
|
242 | - | - | $ 21.2 M | USA |
 |
Myriad Genetics
MYGN
|
52.3 | $ 4.68 | -3.31 % | $ 433 M | USA |
 |
OpGen
OPGN
|
4.66 | - | -16.95 % | $ 1.54 M | USA |
 |
Natera
NTRA
|
81.5 | $ 194.75 | -2.71 % | $ 19.2 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
44.9 | $ 189.32 | -2.94 % | $ 21 B | USA |
 |
Burning Rock Biotech Limited
BNR
|
31.7 | $ 16.24 | -2.46 % | $ 175 M | China |
 |
Organovo Holdings
ONVO
|
79.8 | - | -2.3 % | $ 19.4 M | USA |
 |
Personalis
PSNL
|
55.8 | $ 5.04 | -8.36 % | $ 299 M | USA |
 |
Precipio
PRPO
|
21.1 | $ 29.94 | -5.73 % | $ 48.1 M | USA |
 |
Exagen
XGN
|
51.2 | $ 2.76 | 1.1 % | $ 59.5 M | USA |